CancerConsultants (KC) 22-Sep-09
From Kidney Cancer Resource
Go Back To CancerConsultants (KC)
Broad Range of Patients with Renal Cell Carcinoma Benefit from Sutent®
Researchers from the UK have reported that Sutent® (sunitinib) is safe and effective for a broad population of patients with metastatic renal cell carcinoma. The results of this study were published in the August, 2009 issue of Lancet Oncology.[1]
Sutent is an oral targeted agent that works by inhibiting multiple biologic pathways involved in the growth, replication, and spread of cancer cells. Sutent deprives cancer cells of blood and nutrients needed for growth.
Although Sutent has become standard for the first-line treatment of metastatic RCC, many patients are excluded from clinical trials because they have a poor prognosis or do not meet the inclusion criteria; therefore, the efficacy of Sutent in these subgroups is unclear.
A recent trial included 4,564 patients with metastatic RCC from 52 countries. The study included a broad population of patients who are often excluded from clinical trials: those with brain metastases, non-clear-cell RCC, with Eastern Cooperative Oncology Group (ECOG) performance status of two or higher, or those over age 65. Patients received a median of five treatment cycles, which consisted of 50 milligrams of oral Sutent for four weeks, followed by two weeks off.
There were 3,464 evaluable patients, and the objective response rate was 17%. Median progression-free survival was 10.9 months, and overall survival was 18.4 months. The most common side effects were diarrhea and fatigue.
Comments: These researchers concluded that Sutent is safe and tolerable in subgroups of patients who might otherwise have a lower tolerance to therapy. They suggest that this is encouraging for patients with a poor prognosis who are often excluded from trials.
Reference:
[1] Gore ME, Szcylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: An expanded-access trial. Lancet Oncology. 2009; 10: 757-763.
To View The Original Article Click Here
|
Disclaimer
Kidney Cancer Resource (KCR) is not influenced by sponsors. The information contained herein is not intended as a substitute for the advice of an appropriately qualified and licensed physician or other licensed health care provider. The information provided here is for educational and information purposes only. Early accurate Diagnosis (Dx.) saves lives. Please check with a physician if you suspect you are ill, never ignore Symptoms. To help your health care specialist make an accurate Diagnosis please keep notes of dates, times and details of your Symptoms. We are not offering medical advice nor do we consider links, individuals or articles accessed through this site to be offering medical advice.
E&OE - Errors & Omissions Excepted
As much of the information posted on this Web Site for peoples convenience is of a medical or technical nature, and may be a matter of life or death the E&OE is a Disclaimer showing that to the best of our ability information is accurate and correctly written or transcribed. Before acting on information on this site you are responsible for checking it with your relevant medical team. We can not be held responsible for any Errors & Omissions made; nor for information on links and articles provided in good faith.
